The dose range was based on the efficacy studies in xenograft tumor models9,10,19,20, safety studies in DSG2 transgenic mice (see above), and pilot studies in cynomolgus monkeys that were performed with 2 mg/kg r-JO411. This evidence concerns the gene DSG2 and neoplasm.